Onyx Pharmaceuticals, Inc. develops innovative small-molecule cancer treatments based on a molecular understanding of cancer. The company’s lead product is Nexavar® (sorafenib) tablets, a novel, oral multiple kinase inhibitor that targets proteins involved in both tumor cell proliferation and angiogenesis (the formation of new blood vessels to support cancer cell growth). This product is being developed and marketed in collaboration with Bayer Pharmaceuticals Corporation. Nexavar has been approved by the U.S. and E.U. for treating patients with advanced kidney cancer.